



Genotyping of BKO mice

1. Method used in our animal resource bank

This section describes our method we are routinely using for genotyping BKO mice.

1.1) Primer sequences:

- Primer1: T-Neo 782F
 - Sequence: 5'- CTC GCG CCA GCC GAA CTG TT -3' (20-mer)
- Primer2: T-Neo1351R
 - Sequence: 5'- GTT CGA GGC CAC ACG CGT CA -3' (20-mer)
- Primer3: Wild 3
 - Sequence: 5'- CAT TCC TGC CAA GAC AGT AG -3' (20-mer)
- Primer4: BKO1415-1R
 - Sequence: 5'- ATG GCC TCA GTG TTC AGT GGG -3' (21-mer)

1.2) Reaction mixture:

| | For KO allele | For Wild allele |
|------------------------------------|---------------|-----------------|
| | Tube 1(µL) | Tube 2(µL) |
| Water | 8.6 | 8.6 |
| Primer1 (T-Neo 782F, 10 µM) | 0.2 | |
| Primer2 (T-Neo1351R, 10 µM) | 0.2 | |
| Primer3 (Wild 3, 10 µM) | | 0.2 |
| Primer4 (BKO1415-1R, 10 µM) | | 0.2 |
| Taq polymerase (U/µL) | 10 | 10 |
| DNA extracted from tail (purified) | 1 | 1 |
| total | 20 | 20 |

Taq polymerase: HotStarTaq Master Mix Kit (Qiagen). The enzyme is a chemically modified Taq polymerase for hot start PCR and needs 15-min incubation at 95 °C for activation. Master Mix contains enzyme, dNTP, Mg, etc at 2 x concentration. Please see Qiagen's website for details (<http://www1.qiagen.com/Products/Pcr/HotStarTaqSystem/HotStarTaqMasterMix.aspx>).

1.3) Thermal cycles:

Tube 1 (WT : primer1 and 2)

| | | |
|-------|--------|--------------------------------------|
| 95 °C | 15 min | Enzyme activation and first denature |
| 94 °C | 10 sec | 35 cycles |
| 60 °C | 10 sec | |
| 72 °C | 30 sec | |
| 72 °C | 5 min | once |
| 4 °C | ∞ | |

Thermal cycler: Veriti with 0.2mL tubes.

1.4) Product size:

Primers 1 and 2: 570 bp for KO alleles
Primers 3 and 4: 242 bp for wild-type alleles

1.5) References:

1. Matsuda J et al. (1997) β -Galactosidase-deficient Mouse as an Animal Model for GM1-gangliosidosis. *Glycoconjugate J*, 14:729-736.
2. Itoh M et al. (2001) Development of lysosomal storage in mice with targeted disruption of the β -galactosidase gene: a model of human GM1-gangliosidosis. *Brain Dev*, 23: 379-384.
3. Matsuda J et al. (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. *Proc Natl Acad Sci USA*, 100(26):15912-7.

Nibio_ID=016; February 21st, 2013